- Home
- RILYP vs GALT Comparison
RILYP vs GALT Comparison
Compare RILYP & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RILYP | GALT |
|---|---|---|
| Founded | 1973 | 2000 |
| Country | United States | United States |
| Employees | 1380 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 199.2M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | RILYP | GALT |
|---|---|---|
| Price | $14.59 | $2.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 17.1K | ★ 273.9K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $854,383,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.75 | $1.22 |
| 52 Week High | $15.69 | $7.13 |
Technical Indicators
Market Signals| Indicator | RILYP | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 76.77 | 43.26 |
| Support Level | $5.24 | $2.18 |
| Resistance Level | N/A | $2.60 |
| Average True Range (ATR) | 0.83 | 0.14 |
| MACD | 0.24 | 0.00 |
| Stochastic Oscillator | 80.98 | 41.06 |
Price Performance
Historical ComparisonAbout RILYP B. Riley Financial Inc.
BRC Group Holdings Inc is a diversified holding company offering a platform of businesses, including financial services (with complementary banking and wealth management businesses), telecom, retail, and investments in equity, debt, and venture capital. It serves retail, corporate, capital providers, and individual customers across different business lines. The Group reports its activities in seven reportable business segments: Capital Markets, Wealth Management, Lingo, magicJack, Marconi Wireless, UOL, and Consumer Products. Maximum revenue is generated from the Consumer Products segment, which offers mobile computing accessories and home furnishing products. Geographically, the Group derives its revenue from North America.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.